Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Mallinckrodt
Farmers Insurance
Chinese Patent Office
QuintilesIMS
Daiichi Sankyo
Dow
Chubb
Julphar

Generated: April 19, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TETRABENAZINE

« Back to Dashboard

Clinical Trials for TETRABENAZINE

Trial ID Title Status Sponsor Phase Summary
NCT00219804 Efficacy and Safety of Tetrabenazine in Chorea Completed Prestwick Pharmaceuticals Phase 3 The primary objective of this study was to establish the absolute reduction of chorea in participants with Huntington's disease(HD) treated with tetrabenazine or placebo
NCT00362804 Tetrabenazine for Partial Responders Completed Stanley Medical Research Institute N/A Purpose of Study: A) To improve outcome in large population of antipsychotic patients with schizophrenia or schizoaffective who are only partial responders B) To increase understanding of pharmacology and mechanisms of action underlying antipsychotic effect Hypothesis/Objectives of the Study: Tetrabenazine, through its pre-synaptic action, should augment the post-synaptic effects of an antipsychotic. Background and Rationale for the study: Preliminary evidence that other amine-depleting agents e.g., reserpine, can induce such an effect
NCT00362804 Tetrabenazine for Partial Responders Completed Centre for Addiction and Mental Health N/A Purpose of Study: A) To improve outcome in large population of antipsychotic patients with schizophrenia or schizoaffective who are only partial responders B) To increase understanding of pharmacology and mechanisms of action underlying antipsychotic effect Hypothesis/Objectives of the Study: Tetrabenazine, through its pre-synaptic action, should augment the post-synaptic effects of an antipsychotic. Background and Rationale for the study: Preliminary evidence that other amine-depleting agents e.g., reserpine, can induce such an effect
NCT00632645 Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride Recruiting Assistance Publique - Hôpitaux de Paris Phase 3 Huntington's disease (HD) is autosomal dominant neurodegenerative disease, starting in average (with high variability) in the fourth decade. The disease progression is classically characterized by a cognitive deterioration (cortical-frontal dementia), motor disorders (associating chorea, dystonia and bradykinesia), psychiatric disturbances (combining depression and irritability) and metabolic disorder (cachexia). The disease is fatal within 15 to 20 years in most patients. HD has no cure. Neuroleptics are the main drug used and the only to demonstrate its efficacy on chorea in clinical trials. But neuroleptics have also beneficial and adverse effects on other disease characteristics (motor, psychiatric, cognitive or metabolic). Their profile between beneficial and adverse effects could be different according the neuroleptics and their classification. The aim of this study is to compare beneficial and adverse effects of 3 different neuroleptics in HD.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Clinical Trial Conditions for TETRABENAZINE

Condition Name

Condition Name for TETRABENAZINE
Intervention Trials
Huntington's Disease 2
Huntington Disease 2
Schizophrenia 2
Schizoaffective Disorder 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for TETRABENAZINE
Intervention Trials
Huntington Disease 5
Movement Disorders 2
Schizophrenia 2
Psychotic Disorders 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for TETRABENAZINE

Trials by Country

Trials by Country for TETRABENAZINE
Location Trials
United States 29
Canada 3
France 3
Australia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for TETRABENAZINE
Location Trials
New York 2
Texas 2
Arkansas 1
Colorado 1
District of Columbia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for TETRABENAZINE

Clinical Trial Phase

Clinical Trial Phase for TETRABENAZINE
Clinical Trial Phase Trials
Phase 4 2
Phase 3 4
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for TETRABENAZINE
Clinical Trial Phase Trials
Recruiting 5
Completed 3
Active, not recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for TETRABENAZINE

Sponsor Name

Sponsor Name for TETRABENAZINE
Sponsor Trials
Canadian Network for Observational Drug Effect Studies, CNODES 1
Prestwick Pharmaceuticals 1
Centre Hospitalier Universitaire, Amiens 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for TETRABENAZINE
Sponsor Trials
Other 12
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Mallinckrodt
US Army
Merck
US Department of Justice
Teva
Healthtrust
Federal Trade Commission
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.